Last reviewed · How we verify
RemifentanilMNTX
RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects.
RemifentanilMNTX is a combination of remifentanil (a potent opioid agonist) and methylnaltrexone (a peripheral mu-opioid receptor antagonist) designed to provide analgesia while reducing opioid-induced side effects. Used for Intraoperative analgesia and sedation during anesthesia.
At a glance
| Generic name | RemifentanilMNTX |
|---|---|
| Also known as | Methylnaltrexone, Remifentanil, Relistor, Ultiva |
| Sponsor | Region Örebro County |
| Drug class | Opioid agonist with peripheral opioid antagonist |
| Target | Mu-opioid receptor (agonist: remifentanil; peripheral antagonist: methylnaltrexone) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Analgesia |
| Phase | FDA-approved |
Mechanism of action
Remifentanil acts as a mu-opioid receptor agonist in the central nervous system to produce analgesia and sedation. Methylnaltrexone is a quaternary ammonium derivative of naltrexone that antagonizes mu-opioid receptors peripherally (unable to cross the blood-brain barrier) to counteract gastrointestinal and other peripheral opioid-induced adverse effects while preserving central analgesic effects.
Approved indications
- Intraoperative analgesia and sedation during anesthesia
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Muscle rigidity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RemifentanilMNTX CI brief — competitive landscape report
- RemifentanilMNTX updates RSS · CI watch RSS
- Region Örebro County portfolio CI